Neoplasma. 2013;60(6):676-82. doi: 10.4149/neo_2013_086.
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectively (P<0.001).The most common adverse effects were rash and diarrhoea. In conclusion ertlotinib is effective and well-tolerated in patients with advanced-stage squamous cell NSCLC.
厄洛替尼是一种表皮生长因子受体酪氨酸激酶抑制剂。临床试验已经证实了其在晚期非小细胞肺癌（NSCLC）中的疗效。我们基于临床经验进行了一项大型回顾性研究，旨在证明厄洛替尼在晚期鳞状细胞 NSCLC 患者中的疗效和安全性。共有 375 名晚期（IIIB、IV 期）鳞状细胞 NSCLC 患者接受了厄洛替尼治疗。厄洛替尼一直持续到疾病进展或无法耐受毒性。1 例（0.3%）完全缓解（CR），28 例（7.5%）部分缓解（PR）和 198 例（52.8%）稳定疾病（SD）。总缓解率（ORR）和疾病控制率（DCR）分别为 7.8%和 60.5%。中位无进展生存期（PFS）为 3.0 个月，中位总生存期（OS）为 7.6 个月。CR/PR、SD 和 PD 患者的 PFS 分别为 7.6、3.9 和 1.0 个月，差异具有统计学意义（P<0.001）。CR/PR、SD 和 PD 患者的 OS 分别为 13.3、10.9 和 3.8 个月，差异具有统计学意义（P<0.001）。最常见的不良反应是皮疹和腹泻。总之，厄洛替尼在晚期鳞状细胞 NSCLC 患者中有效且耐受性良好。
